Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of EQ001 in subjects with Acute Graft Versus Host Disease (aGVHD).
The study will enroll approximately 100 subjects in two (2) parts:
Part A is an open label study and will enroll approximately 40 evaluable subjects with aGVHD across 4 cohorts. The total number of patients will depend on the number of dose escalations necessary to enable a decision to be made on the recommended dose to take forward into Part B of the study. The planned dose escalation will start with cohort 1, where subjects will receive EQ001 administered intravenously every two weeks for a total of 5 doses.
Part B is a randomized, double-blind, placebo-controlled study and will enroll approximately 60 additional subjects, randomized in a 2:1 ratio to either active treatment EQ001 (40) or placebo (20). Subjects will receive either EQ001 or placebo administered intravenously every two weeks for a total of 5 doses.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EQ001 Dose Escalation (Part A) | Experimental | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses. |
|
| EQ001 (Part B) | Experimental | EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses. |
|
| EQ001 Placebo (Part B) | Placebo Comparator | Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EQ001 | Biological | Itolizumab [Bmab 600]) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Treatment Emergent Adverse Events | Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. | Study Day 85 |
| Overall Response Rate | Overall Response Rate (ORR) is defined as the number of subjects with a partial response (PR), very good partial response (VGPR), or complete response (CR) who are alive at Day 29. Subjects must not have received new systemic therapy for aGVHD before the Day 29 Visit. | Study Day 29 |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Maximum EQ001serum Concentration, Tmax | Time to maximum EQ001 serum concentration, Tmax | Day 337 |
| Maximum EQ001 Serum Drug Concentration, Cmax | Maximum EQ001 serum drug concentration, Cmax |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joel Rothman | Equillium | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | United States | ||
| University of Florida Health Shands Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35484649 | Derived | Rambaldi B, Kim HT, Arihara Y, Asano T, Reynolds C, Manter M, Halpern M, Weber A, Koreth J, Cutler C, Gooptu M, Nikiforow S, Ho VT, Antin JH, Romee R, Ampudia J, Ng C, Connelly S, Soiffer RJ, Ritz J. Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. Haematologica. 2022 Nov 1;107(11):2617-2629. doi: 10.3324/haematol.2021.280444. |
| Label | URL |
|---|---|
| Company website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Part B of the study was not conducted.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | EQ001 Dose Escalation (Part A) 0.4mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 0.4mg/kg EQ001: Itolizumab [Bmab 600] |
| FG001 | EQ001 Dose Escalation (Part A) 0.8mg/kg |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 24, 2021 | Mar 10, 2025 |
Not provided
Not provided
Part A is an open label 3+3 dose escalation Part B is blinded and randomized 2:1
Not provided
Not provided
Part B will be blinded to all study staff that has direct access to the subjects and the sponsor. The site's pharmacist or designee will be unblinded to prepare the study drug.
| EQ001 Placebo | Biological | EQ001 Placebo |
|
| Study Day 337 |
| Minimum EQ001 Serum Drug Concentration, Cmin | Minimum EQ001 serum drug concentration prior to next dose, Cmin | Study Day 337 |
| Total EQ001 Exposure Across Time, AUC (From Zero to Infinity) | Total EQ001 exposure across time, AUC (from zero to infinity) | Study Day 337 |
| Half Life of EQ001, t1/2 | Half life of EQ001, t1/2 | Study Day 337 |
| Volume of Distribution of EQ001, Vd | Volume of distribution of EQ001, Vd | Study Day 337 |
| Clearance, Cl | Clearance, Cl | Study Day 337 |
| Inflammatory Markers | Including but not limited to: IL-1β, IL-2, IL-6, IL-17, IL-21, IL-22, IL-23, IFN-γ, and TGF-β, C-reactive protein | Study Day 337 |
| CD6 Receptor Expression Levels | CD6 receptor expression levels - percent of baseline | Study Day 85 |
| Gainesville |
| Florida |
| 32610 |
| United States |
| University of Miami - Miller School of Medicine | Miami | Florida | 33136 | United States |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | United States |
| Emory University Hospital | Atlanta | Georgia | 30322 | United States |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States |
| University of Michigan - C.S. Mott Children's Hospital | Ann Arbor | Michigan | 48109 | United States |
| Washington University and Barnes Jewish Heart & Vascular Center | St Louis | Missouri | 63110 | United States |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | United States |
| University of North Carolina Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | United States |
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | United States |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15232 | United States |
| TriStar Centennial Medical Center (SCRI) | Nashville | Tennessee | 53719 | United States |
| Intermountain Healthcare | Salt Lake City | Utah | 84103 | United States |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-4433 | United States |
Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 0.8mg/kg
EQ001: Itolizumab [Bmab 600]
| FG002 | EQ001 Dose Escalation (Part A) 1.6mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 1.6mg/kg EQ001: Itolizumab [Bmab 600] |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | EQ001 Dose Escalation (Part A) 0.4mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 0.4mg/kg EQ001: Itolizumab [Bmab 600] |
| BG001 | EQ001 Dose Escalation (Part A) 0.8mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 0.8mg/kg EQ001: Itolizumab [Bmab 600] |
| BG002 | EQ001 Dose Escalation (Part A) 1.6mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 1.6mg/kg EQ001: Itolizumab [Bmab 600] |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Treatment Emergent Adverse Events | Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. | Posted | Count of Participants | Participants | Study Day 85 |
|
|
| |||||||||||||||||||||||||||||||||
| Primary | Overall Response Rate | Overall Response Rate (ORR) is defined as the number of subjects with a partial response (PR), very good partial response (VGPR), or complete response (CR) who are alive at Day 29. Subjects must not have received new systemic therapy for aGVHD before the Day 29 Visit. | Posted | Count of Participants | Participants | Study Day 29 |
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Time to Maximum EQ001serum Concentration, Tmax | Time to maximum EQ001 serum concentration, Tmax | Not Posted | Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | Maximum EQ001 Serum Drug Concentration, Cmax | Maximum EQ001 serum drug concentration, Cmax | Not Posted | Study Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | Minimum EQ001 Serum Drug Concentration, Cmin | Minimum EQ001 serum drug concentration prior to next dose, Cmin | Not Posted | Study Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | Total EQ001 Exposure Across Time, AUC (From Zero to Infinity) | Total EQ001 exposure across time, AUC (from zero to infinity) | Not Posted | Study Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | Half Life of EQ001, t1/2 | Half life of EQ001, t1/2 | Not Posted | Study Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | Volume of Distribution of EQ001, Vd | Volume of distribution of EQ001, Vd | Not Posted | Study Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | Clearance, Cl | Clearance, Cl | Not Posted | Study Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | Inflammatory Markers | Including but not limited to: IL-1β, IL-2, IL-6, IL-17, IL-21, IL-22, IL-23, IFN-γ, and TGF-β, C-reactive protein | Not Posted | Study Day 337 | Participants | |||||||||||||||||||||||||||||||||||||
| Secondary | CD6 Receptor Expression Levels | CD6 receptor expression levels - percent of baseline | Posted | Mean | Standard Deviation | Percent of baseline | Study Day 85 |
|
|
Adverse Events (AEs) were collected from signing of the informed consent form through the long-term follow-up visit at Day 337.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | EQ001 Dose Escalation (Part A) 0.4mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 0.4mg/kg. EQ001: Itolizumab [Bmab 600] | 1 | 4 | 2 | 4 | 4 | 4 |
| EG001 | EQ001 Dose Escalation (Part A) 0.8mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 0.8mg/kg. EQ001: Itolizumab [Bmab 600] | 7 | 17 | 9 | 17 | 17 | 17 |
| EG002 | EQ001 Dose Escalation (Part A) 1.6mg/kg | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses at 1.6mg/kg. EQ001: Itolizumab [Bmab 600] | 6 | 9 | 8 | 9 | 9 | 9 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Sepsis | Infections and infestations | Systematic Assessment |
| ||
| Adenovirus infection | Infections and infestations | Systematic Assessment |
| ||
| Arthritis bacterial | Infections and infestations | Systematic Assessment |
| ||
| COVID-19 | Infections and infestations | Systematic Assessment |
| ||
| COVID-19 pneumonia | Infections and infestations | Systematic Assessment |
| ||
| Klebsiella sepsis | Infections and infestations | Systematic Assessment |
| ||
| Nocardiosis | Infections and infestations | Systematic Assessment |
| ||
| pulmonary mucormycosis | Infections and infestations | Systematic Assessment |
| ||
| Pulmonary sepsis | Infections and infestations | Systematic Assessment |
| ||
| Skin infection | Infections and infestations | Systematic Assessment |
| ||
| Staphylococcal sepsis | Infections and infestations | Systematic Assessment |
| ||
| Graft versus host disease | Immune system disorders | Systematic Assessment |
| ||
| Graft versus host disease in gastrointestinal tract | Immune system disorders | Systematic Assessment |
| ||
| Acute graft versus host disease | Immune system disorders | Systematic Assessment |
| ||
| Cardiac arrest | Cardiac disorders | Systematic Assessment |
| ||
| Atrial fibrillation | Cardiac disorders | Systematic Assessment |
| ||
| Atrial flutter | Cardiac disorders | Systematic Assessment |
| ||
| Pulseless electrical activity | Cardiac disorders | Systematic Assessment |
| ||
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Intestinal infarction | Gastrointestinal disorders | Systematic Assessment |
| ||
| Lower gastrointestinal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
| ||
| Retroperitoneal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
| ||
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Hypoxia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Physical deconditioning | General disorders | Systematic Assessment |
| ||
| Pyrexia | General disorders | Systematic Assessment |
| ||
| Cholecystitis | Hepatobiliary disorders | Systematic Assessment |
| ||
| Hepatic cirrhosis | Hepatobiliary disorders | Systematic Assessment |
| ||
| Hepatitis fulminant | Hepatobiliary disorders | Systematic Assessment |
| ||
| Wound dehiscence | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Myopathy | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Acute myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Cognitive disorder | Nervous system disorders | Systematic Assessment |
| ||
| Substance-induced psychotic disorder | Psychiatric disorders | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Oedema peripheral | General disorders | Non-systematic Assessment |
| ||
| Fatigue | General disorders | Systematic Assessment |
| ||
| Chills | General disorders | Systematic Assessment |
| ||
| Generalised oedema | General disorders | Systematic Assessment |
| ||
| Asthenia | General disorders | Systematic Assessment |
| ||
| Pyrexia | General disorders | Systematic Assessment |
| ||
| Hypokalaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypomagnesaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hyperglycaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Decreased appetite | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hyperkalaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypoalbuminaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypophosphataemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypermagnesaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hyponatraemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Dehydration | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypercalcaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypernatraemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hyperuricaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Vitamin D deficiency | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment |
| ||
| Dry mouth | Gastrointestinal disorders | Systematic Assessment |
| ||
| Lower gastrointestinal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
| ||
| Abdominal distension | Gastrointestinal disorders | Systematic Assessment |
| ||
| Gastrooesophageal reflux disease | Gastrointestinal disorders | Systematic Assessment |
| ||
| Nausea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Stomatitis | Gastrointestinal disorders | Systematic Assessment |
| ||
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
| ||
| Platelet count decreased | Investigations | Systematic Assessment |
| ||
| Blood alkaline phosphate increased | Investigations | Systematic Assessment |
| ||
| Neutrophil count decreased | Investigations | Systematic Assessment |
| ||
| Alanine aminotransferase increased | Investigations | Systematic Assessment |
| ||
| Lymphocyte count decreased | Investigations | Systematic Assessment |
| ||
| Aspartate aminotransferase increased | Investigations | Systematic Assessment |
| ||
| Blood bilirubin increased | Investigations | Systematic Assessment |
| ||
| Blood creatinine increased | Investigations | Systematic Assessment |
| ||
| Gamma-glutamyltransferase increased | Investigations | Systematic Assessment |
| ||
| International normalised ratio increased | Investigations | Systematic Assessment |
| ||
| White blood cell count decreased | Investigations | Systematic Assessment |
| ||
| Blood lactic acid increased | Investigations | Non-systematic Assessment |
| ||
| Urinary tract infection | Infections and infestations | Systematic Assessment |
| ||
| Bacteraemia | Infections and infestations | Systematic Assessment |
| ||
| Cytomegalovirus infection | Infections and infestations | Systematic Assessment |
| ||
| Sepsis | Infections and infestations | Systematic Assessment |
| ||
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Hiccups | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Hypoxia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Skin ulcer | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Erythema | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Skin exfoliation | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Anaemia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Neutropenia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Thrombocytopenia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Fall | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Contusion | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Infusion related reaction | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Muscular weakness | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Muscle spasms | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Osteopenia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Pain in extremity | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Sinus tachycardia | Cardiac disorders | Systematic Assessment |
| ||
| Atrial fibrillation | Cardiac disorders | Systematic Assessment |
| ||
| Cardiac arrest | Cardiac disorders | Systematic Assessment |
| ||
| Insomnia | Psychiatric disorders | Systematic Assessment |
| ||
| Agitation | Psychiatric disorders | Systematic Assessment |
| ||
| Depression | Psychiatric disorders | Systematic Assessment |
| ||
| Confusional state | Psychiatric disorders | Systematic Assessment |
| ||
| Dizziness | Nervous system disorders | Systematic Assessment |
| ||
| Headache | Nervous system disorders | Systematic Assessment |
| ||
| Graft versus host disease | Immune system disorders | Systematic Assessment |
| ||
| Graft versus host disease in gastrointestinal tract | Immune system disorders | Systematic Assessment |
| ||
| Hypogammaglobulinaemia | Immune system disorders | Systematic Assessment |
| ||
| Haematuria | Renal and urinary disorders | Systematic Assessment |
| ||
| Acute kidney injury | Renal and urinary disorders | Systematic Assessment |
| ||
| Dysuria | Renal and urinary disorders | Systematic Assessment |
| ||
| Hypertension | Vascular disorders | Non-systematic Assessment |
| ||
| Hypotension | Vascular disorders | Systematic Assessment |
| ||
| Orthostatic hypotension | Vascular disorders | Systematic Assessment |
| ||
| Vision blurred | Eye disorders | Systematic Assessment |
| ||
| Adrenal insufficiency | Endocrine disorders | Systematic Assessment |
| ||
| Cholecystitis | Hepatobiliary disorders | Systematic Assessment |
| ||
| Chest discomfort | General disorders | Systematic Assessment |
| ||
| Chest Pain | General disorders | Systematic Assessment |
| ||
| Influenza like illness | General disorders | Systematic Assessment |
| ||
| Localised oedema | General disorders | Systematic Assessment |
| ||
| Mucosal dryness | General disorders | Systematic Assessment |
| ||
| Non-cardiac chest pain | General disorders | Systematic Assessment |
| ||
| Physical deconditioning | General disorders | Systematic Assessment |
| ||
| Gout | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hyperferritinaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypocalcaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hypoglycaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Lactose intolerance | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Metabolic acidosis | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Vitamin B complex deficiency | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Abdominal pain lower | Gastrointestinal disorders | Systematic Assessment |
| ||
| Abdominal pain upper | Gastrointestinal disorders | Systematic Assessment |
| ||
| Anal fissure | Gastrointestinal disorders | Systematic Assessment |
| ||
| Ascites | Gastrointestinal disorders | Systematic Assessment |
| ||
| Colitis | Gastrointestinal disorders | Systematic Assessment |
| ||
| Constipation | Gastrointestinal disorders | Systematic Assessment |
| ||
| Dyspepsia | Gastrointestinal disorders | Systematic Assessment |
| ||
| Dysphagia | Gastrointestinal disorders | Systematic Assessment |
| ||
| Haematochezia | Gastrointestinal disorders | Systematic Assessment |
| ||
| Haemorrhoids | Gastrointestinal disorders | Systematic Assessment |
| ||
| Ileus | Gastrointestinal disorders | Systematic Assessment |
| ||
| Intestinal infarction | Gastrointestinal disorders | Systematic Assessment |
| ||
| Retroperitoneal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
| ||
| Blood albumin decreased | Investigations | Systematic Assessment |
| ||
| Blood lactate dehydrogenase increased | Investigations | Systematic Assessment |
| ||
| Blood urea increased | Investigations | Systematic Assessment |
| ||
| Corona virus test positive | Investigations | Systematic Assessment |
| ||
| Ejection fraction decreased | Investigations | Systematic Assessment |
| ||
| Electrocardiogram QT prolonged | Investigations | Systematic Assessment |
| ||
| Haptoglobin decreased | Investigations | Systematic Assessment |
| ||
| Liver function test increased | Investigations | Systematic Assessment |
| ||
| Oxygen saturation decreased | Investigations | Systematic Assessment |
| ||
| Transaminases increased | Investigations | Systematic Assessment |
| ||
| Adenovirus infection | Infections and infestations | Systematic Assessment |
| ||
| Arthritis bacterial | Infections and infestations | Systematic Assessment |
| ||
| BK virus infection | Infections and infestations | Systematic Assessment |
| ||
| COVID-19 | Infections and infestations | Systematic Assessment |
| ||
| COVID-19 pneumonia | Infections and infestations | Systematic Assessment |
| ||
| Candida infection | Infections and infestations | Systematic Assessment |
| ||
| Clostridium difficile colitis | Infections and infestations | Systematic Assessment |
| ||
| Clostridium difficile infection | Infections and infestations | Systematic Assessment |
| ||
| Cytomegalovirus infection reactivation | Infections and infestations | Systematic Assessment |
| ||
| Cytomegalovirus viraemia | Infections and infestations | Systematic Assessment |
| ||
| Endocarditis | Infections and infestations | Systematic Assessment |
| ||
| Enterococcal bacteraemia | Infections and infestations | Systematic Assessment |
| ||
| Epstein-Barr virus infection reactivation | Infections and infestations | Systematic Assessment |
| ||
| Influenza | Infections and infestations | Systematic Assessment |
| ||
| Klebsiella sepsis | Infections and infestations | Systematic Assessment |
| ||
| Nocardiosis | Infections and infestations | Systematic Assessment |
| ||
| Oral candidiasis | Infections and infestations | Systematic Assessment |
| ||
| Parainfluenzae virus infection | Infections and infestations | Systematic Assessment |
| ||
| Pharyngitis | Infections and infestations | Systematic Assessment |
| ||
| Pneumonia | Infections and infestations | Systematic Assessment |
| ||
| Pulmonary mucormycosis | Infections and infestations | Systematic Assessment |
| ||
| Pulmonary sepsis | Infections and infestations | Systematic Assessment |
| ||
| Sialoadenitis | Infections and infestations | Systematic Assessment |
| ||
| Skin infection | Infections and infestations | Systematic Assessment |
| ||
| Staphylococcal sepsis | Infections and infestations | Systematic Assessment |
| ||
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
| ||
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Atelectasis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Pleuritic Pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Sneezing | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Wheezing | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Decubitus ulcer | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Dermatitis acneiform | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Dermatitis bullous | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Dermatitis contact | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Dry skin | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Eczema | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Leukoplakia | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Onychomadesis | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Pigmentation disorder | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Pruritus | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Rash maculo-papular | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Skin hypopigmentation | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Skin weeping | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Febrile neutropenia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Leukopenia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Thrombotic microangiopathy | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Skin abrasion | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Spinal compression fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Vascular access complication | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Wound dehiscence | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Chondrocalcinosis pyrophosphate | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Myopathy | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Neck pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Osteonecrosis | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Osteoporosis | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Angina pectoris | Cardiac disorders | Systematic Assessment |
| ||
| Atrial flutter | Cardiac disorders | Systematic Assessment |
| ||
| Bradycardia | Cardiac disorders | Systematic Assessment |
| ||
| Pericardial effusion | Cardiac disorders | Systematic Assessment |
| ||
| Pulseless electrical activity | Cardiac disorders | Systematic Assessment |
| ||
| Tachycardia | Cardiac disorders | Systematic Assessment |
| ||
| Delirium | Psychiatric disorders | Systematic Assessment |
| ||
| Intensive care unit delirium | Psychiatric disorders | Systematic Assessment |
| ||
| Irritability | Psychiatric disorders | Systematic Assessment |
| ||
| Substance-induced psychotic disorder | Psychiatric disorders | Systematic Assessment |
| ||
| Cognitive disorder | Nervous system disorders | Systematic Assessment |
| ||
| Dizziness postural | Nervous system disorders | Systematic Assessment |
| ||
| Dysgeusia | Nervous system disorders | Systematic Assessment |
| ||
| Embolic stroke | Nervous system disorders | Systematic Assessment |
| ||
| Encephalopathy | Nervous system disorders | Systematic Assessment |
| ||
| Hypoaesthesia | Nervous system disorders | Systematic Assessment |
| ||
| Lethargy | Nervous system disorders | Systematic Assessment |
| ||
| Peripheral sensory neuropathy | Nervous system disorders | Systematic Assessment |
| ||
| Acute graft versus host disease | Immune system disorders | Systematic Assessment |
| ||
| Hydronephrosis | Renal and urinary disorders | Systematic Assessment |
| ||
| Nephrolithiasis | Renal and urinary disorders | Systematic Assessment |
| ||
| Urinary retention | Renal and urinary disorders | Systematic Assessment |
| ||
| Angiopathy | Vascular disorders | Systematic Assessment |
| ||
| Embolism | Vascular disorders | Systematic Assessment |
| ||
| Eye irritation | Eye disorders | Systematic Assessment |
| ||
| Lacrimation increased | Eye disorders | Systematic Assessment |
| ||
| Scleral haemorrhage | Eye disorders | Systematic Assessment |
| ||
| Hepatic cirrhosis | Hepatobiliary disorders | Systematic Assessment |
| ||
| Hepatitis fulminant | Hepatobiliary disorders | Systematic Assessment |
| ||
| Ear congestion | Ear and labyrinth disorders | Systematic Assessment |
| ||
| Tinnitus | Ear and labyrinth disorders | Systematic Assessment |
| ||
| Acute myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Melanocytic naevus | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Azoospermia | Reproductive system and breast disorders | Systematic Assessment |
| ||
| Breast pain | Reproductive system and breast disorders | Systematic Assessment |
| ||
| Scrotal oedema | Reproductive system and breast disorders | Systematic Assessment |
| ||
| Dental implantation | Surgical and medical procedures | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Operations | Equillium | 858-240-1200 | clinicaltrials@equilliumbio.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Feb 15, 2022 | Mar 10, 2025 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D006086 | Graft vs Host Disease |
| ID | Term |
|---|---|
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000597346 | itolizumab |
Not provided
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Participants |
|
|
|